Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 28:12:2335-2342.
doi: 10.2147/OTT.S189825. eCollection 2019.

Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis

Shu Deng  1 , Shenyun Lin  1 , Jianping Shen  1 , Yuqing Zeng  2
Affiliations

Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis

Shu Deng et al. Onco Targets Ther. .

Abstract

Objective: To compare cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and CHOP plus etoposide (CHOPE) with regard to outcomes including efficacy and safety for patients with peripheral T-cell lymphoma (PTCL).

Methods: Relevant literature was searched using PubMed, Embase, Wanfang, and CNKI for eligible trials comparing CHOP with CHOPE for treatment of PTCL. The following outcomes of PTCL patients were considered: complete response (CR), partial response (PR), overall response rate (ORR), and adverse events (AEs; grade >3). Risk ratios (RRs) were appropriately derived from fixed-effects or random-effects models.

Results: A total of five prospective or retrospective articles with 1,560 patients were elected for the meta-analysis. There were no significant differences in CR (RR =1.11, 95% CI: 0.73-1.67, P=0.632), PR (RR =1.40, 95% CI: 0.52-3.76, P=0.504), and ORR (RR =1.25, 95% CI: 0.93-1.69, P=0.146) between the CHOP and CHOPE groups. However, AEs including anemia (RR =1.69, 95% CI: 1.33-2.16, P<0.001) and thrombocytopenia (RR =1.43, 95% CI: 1.15-1.77, P=0.001) were significantly increased in CHOPE group compared to that in CHOP group.

Conclusion: Meta-analysis suggested that there were no differences in therapeutic effect for patients with PTCL between CHOP and CHOPE groups with regards to CR, PR, and ORR, whereas the CHOPE group had significantly increased AEs (anemia and thrombocytopenia) compared to CHOP group.

Keywords: adverse events; complete response; overall response rate; partial response; peripheral T-cell lymphoma.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flow chart of study literature selection for meta-analysis. Abbreviations: CHOPE, cyclophosphamide, doxorubicin, vincristine, and prednisone plus etoposide; PTCL, peripheral T-cell lymphoma.
Figure 2
Figure 2
Meta-analysis results of CHOP and CHOPE for (A) CR, (B) PR, and (C) ORR. Note: Weights are from random-effects analysis. Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CHOPE, cyclophosphamide, doxorubicin, vincristine, and prednisone plus etoposide; CR, complete response; PR, partial response; ORR, overall response rate; RR, risk ratio.
Figure 3
Figure 3
Meta-analysis results of CHOP and CHOPE for adverse events including (A) thrombocytopenia, (B) neutropenia, (C) anemia, (D) leukopenia, and (E) vomiting. Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CHOPE, cyclophosphamide, doxorubicin, vincristine, and prednisone plus etoposide; RR, risk ratio.
Figure 3
Figure 3
Meta-analysis results of CHOP and CHOPE for adverse events including (A) thrombocytopenia, (B) neutropenia, (C) anemia, (D) leukopenia, and (E) vomiting. Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CHOPE, cyclophosphamide, doxorubicin, vincristine, and prednisone plus etoposide; RR, risk ratio.
See this image and copyright information in PMC

References

    1. Yang YT, Tai CJ, Chen C, et al. Highly diverse efficacy of salvage treatment regimens for relapsed or refractory peripheral T-cell lymphoma: a systematic review. PLoS One. 2016;11(10):e0161811. - PMC - PubMed
    1. Park S, Ko YH. Peripheral T cell lymphoma in Asia. Int J Hematol. 2014;99(3):227–239. - PubMed
    1. Armitage JO. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(5):511–519. - PubMed
    1. Vose J, Armitage J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130. - PubMed
    1. Zelenetz AD, Abramson JS, Advani RH, et al. Nccn clinical practice guidelines in oncology: non-Hodgkin’s lymphomas. J Natl Compr Canc Netw. 2010;8(3):288–334. - PubMed